Browse by |
Current Controversies, Recent Developments and Emerging Strategies in the Management of Breast Cancer: A Clinical Investigator Think TankTARGET AUDIENCE This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer. OVERVIEW OF ACTIVITY Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — clinicians must be well informed of these advances. To bridge the gap between research and practice, this program features leading oncology investigators debating the merits, applications and limitations of emerging data sets. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY This CME activity consists of a video component. The participant should watch the video. CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ana Maria Gonzalez-Angulo, MD, MSc Advisory Committee: Bayer HealthCare Pharmaceuticals; Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation; PI on Trial: Genomic Health Inc. William J Gradishar, MD No real or apparent conflicts of interest to report. Daniel F Hayes, MD Paid Research: Novartis Pharmaceuticals Corporation, Pfizer Inc, Veridex LLC; Stock Ownership: Oncimmune Ltd. Ian E Krop, MD, PhD Consulting Agreement: Novartis Pharmaceuticals Corporation; Investigator on Trial: Genentech BioOncology. Hannah M Linden, MD Paid Research: Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Pfizer Inc. Eleftherios P Mamounas, MD, MPH Advisory Committee: Genomic Health Inc, Novartis Pharmaceuticals Corporation; Consulting Agreement: Genomic Health Inc; Speakers Bureau: Celgene Corporation, Genomic Health Inc. Kathy D Miller, MD Advisory Committee: Clovis Oncology, Genentech BioOncology; Clinical Trials: Geron, Merrimack Pharmaceuticals; Consulting Agreements: Bristol-Myers Squibb Company, Roche Laboratories Inc; Paid Research: Clovis Oncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. Charles L Vogel, MD Advisory Committee: Amgen Inc, Aveo Pharmaceuticals, Genentech BioOncology, Roche Laboratories Inc; Speakers Bureau: Amgen Inc, GlaxoSmithKline. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Abbott Laboratories, Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation. Hardware/Software Requirements: Last review date: May 2012 |